Published in Diabetologia on March 27, 2012
Action to Control Cardiovascular Risk in Diabetes (ACCORD) (ACCORD) | NCT00000620
Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol (2013) 2.17
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Fibroblast growth factor 23 and incident CKD in type 2 diabetes. Clin J Am Soc Nephrol (2014) 0.79
Polyunsaturated fatty acyl-coenzyme As are inhibitors of cholesterol biosynthesis in zebrafish and mice. Dis Model Mech (2013) 0.78
Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Invest (2017) 0.75
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med (2006) 32.81
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.14
Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci (2004) 3.86
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant (2000) 2.99
Use of fibrates in the United States and Canada. JAMA (2011) 2.82
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia (2010) 1.88
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis (2005) 1.44
Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol (2007) 1.24
Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis (2008) 1.15
Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421]. Curr Control Trials Cardiovasc Med (2001) 1.13
Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron (2002) 1.11
Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics (2004) 1.08
Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care (2009) 1.02
Fibrate-induced increase in blood urea and creatinine. Nephrol Dial Transplant (2001) 0.99
Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol (1998) 0.98
Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol (2004) 0.98
[Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency]. Nephrologie (1999) 0.87
The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. Eur J Pharmacol (2010) 0.82
Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther (2002) 0.81
Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. Atherosclerosis (2005) 0.79
Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. J Am Soc Nephrol (2001) 0.78
An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum (2008) 4.25
The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2005) 3.97
Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum (2006) 3.03
An analysis of the natural history of cavernous angiomas. J Neurosurg (1991) 2.97
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation (2000) 2.94
Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest (1992) 2.80
Lessons from experienced guideline implementers: attend to many factors and use multiple strategies. Jt Comm J Qual Improv (2000) 2.77
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
The cost to health plans of poor glycemic control. Diabetes Care (1997) 2.55
Two sites for modulation of human sympathetic activity by arterial baroreceptors? J Physiol (2001) 2.51
Evaluation of subsecond gated helical CT for quantification of coronary artery calcium and comparison with electron beam CT. AJR Am J Roentgenol (2000) 2.49
Psychological monitoring of overtraining and staleness. Br J Sports Med (1987) 2.33
Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest (1993) 2.24
Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev (1999) 2.24
Overview of the MHC fine mapping data. Diabetes Obes Metab (2009) 2.24
The human homolog of rat Jagged1 expressed by marrow stroma inhibits differentiation of 32D cells through interaction with Notch1. Immunity (1998) 2.23
B-mode-detected carotid artery plaque in a general population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke (1994) 2.19
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med (2001) 2.14
Mechanisms of carcinogenesis induced by alkylating agents. Biochim Biophys Acta (1985) 2.13
Epidemiology of headache and migraine in women. J Neurol Neurosurg Psychiatry (1971) 2.11
Predicting lower-extremity injuries among habitual runners. Arch Intern Med (1989) 2.06
Is hypertriglyceridemia a risk factor for atherosclerotic cardiovascular disease? A simple question with a complicated answer. Ann Intern Med (1997) 2.04
Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. Circulation (1990) 1.99
Sex-specific associations of magnetic resonance imaging-derived intra-abdominal and subcutaneous fat areas with conventional anthropometric indices. The Atherosclerosis Risk in Communities Study. Am J Epidemiol (1996) 1.99
Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med (1994) 1.96
Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest (1986) 1.96
Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum (2002) 1.92
Reasons for grounding airline pilots. Trans Soc Occup Med (1967) 1.92
The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70. J Biol Chem (1997) 1.87
Brachial flow-mediated vasodilator responses in population-based research: methods, reproducibility and effects of age, gender and baseline diameter. J Cardiovasc Risk (2001) 1.87
Variants in intron 13 of the ELMO1 gene are associated with diabetic nephropathy in African Americans. Ann Hum Genet (2009) 1.85
Serological characterization of 8 Haemophilus pleuropneumoniae strains and proposal of a new serotype: serotype 8. Acta Vet Scand (1984) 1.79
Prognostic significance of progression of coronary atherosclerosis. Circulation (1993) 1.79
Relationship between modifiable health risks and short-term health care charges. JAMA (1999) 1.77
Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Biol Chem (1991) 1.73
Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet. Arterioscler Thromb Vasc Biol (2001) 1.72
Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol (2001) 1.70
Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J Lipid Res (1993) 1.68
Chronic renal artery occlusion: nephrectomy versus revascularization. J Vasc Surg (1999) 1.66
Long-term exercise and its effect on balance in older, osteoarthritic adults: results from the Fitness, Arthritis, and Seniors Trial (FAST). J Am Geriatr Soc (2000) 1.65
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract (2011) 1.59
Statin treatment and adherence to national cholesterol guidelines after ischemic stroke. Neurology (2006) 1.57
The effects of propofol on cerebral blood flow velocity and cerebral oxygen extraction during cardiopulmonary bypass. Anesth Analg (1998) 1.57
Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet (1997) 1.56
Multimethod research: approaches for integrating qualitative and quantitative methods. J Gen Intern Med (1994) 1.54
Adipose tissue determinations in cadavers--a comparison between cross-sectional planimetry and computed tomography. Int J Obes (1990) 1.54
HDL-subpopulation patterns in response to reductions in dietary total and saturated fat intakes in healthy subjects. Am J Clin Nutr (1999) 1.54
Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. J Intern Med (2009) 1.53
The individual over time: time series applications in health care research. J Clin Epidemiol (1990) 1.53
Improving diabetes care in a large health care system: an enhanced primary care approach. Jt Comm J Qual Improv (2000) 1.51
High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med (1997) 1.48
Biological implications of the instability of the N-glycosidic bone of 3-methyldeoxyadenosine in DNA. Biochim Biophys Acta (1973) 1.48
Psychological characterization of the elite female distance runner. Int J Sports Med (1987) 1.48
Firing properties of single muscle vasoconstrictor neurons in the sympathoexcitation associated with congestive heart failure. Circulation (1999) 1.48
High thoracic epidural anesthesia does not inhibit sympathetic nerve activity in the lower extremities. Anesthesiology (1999) 1.46
The effects of acute exercise on sleep: a quantitative synthesis. Sleep (1997) 1.45
Combined lipase deficiency (cld): a lethal mutation on chromosome 17 of the mouse. Science (1983) 1.44
Regulated Co-translational ubiquitination of apolipoprotein B100. A new paradigm for proteasomal degradation of a secretory protein. J Biol Chem (1998) 1.44
Sympathetic muscle nerve activity during sleep in man. Brain (1991) 1.44
Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) Am J Cardiol (1995) 1.43
Reducing total dietary fat without reducing saturated fatty acids does not significantly lower total plasma cholesterol concentrations in normal males. Am J Clin Nutr (1992) 1.42
Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk (1999) 1.40
Phobic reaction to flying. Proc R Soc Med (1970) 1.39
Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey. J Clin Invest (1982) 1.39
Comparative studies of the hepatocarcinogen N,N-dimethylnitrosamine in vivo: reaction sites in rat liver DNA and the significance of their relative stabilities. Br J Cancer (1973) 1.38
Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc Natl Acad Sci U S A (1998) 1.38
Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest (1993) 1.37
Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation (1995) 1.36
Mood disturbance following increased training in swimmers. Med Sci Sports Exerc (1988) 1.35
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab (2012) 1.34
Depressed baroreflex sensitivity in patients with obstructive sleep apnea. Am J Respir Crit Care Med (1996) 1.33
Repair of alkylated purines in the hepatic DNA of mitochondria and nuclei in the rat. Carcinogenesis (1988) 1.32
A possible explanation for the differential cancer incidence in the intestine, based on distribution of the cytotoxic effects of carcinogens in the murine large bowel. Carcinogenesis (1992) 1.32
Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting. J Am Pharm Assoc (Wash) (2000) 1.31
Relations of intimal-medial thickness among sites within the carotid artery as evaluated by B-mode ultrasound. ARIC Investigators. Atherosclerosis Risk in Communities. Stroke (1994) 1.30
Naturally occurring muscle pain during exercise: assessment and experimental evidence. Med Sci Sports Exerc (1997) 1.30
Effects of age, education, and physician advice on utilization of screening mammography. J Am Geriatr Soc (1989) 1.29
Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation (1997) 1.29
Hypercapnia and hypoxia: chemoreceptor-mediated control of locus coeruleus neurons and splanchnic, sympathetic nerves. Brain Res (1981) 1.28
Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol (2002) 1.28
Contribution of visceral fat mass to the insulin resistance of aging. Metabolism (1995) 1.25
Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss. J Clin Invest (1985) 1.23
Extension of the Haseman-Elston method to multiple alleles and multiple loci: theory and practice for candidate genes. Ann Hum Genet (1997) 1.21
Associations of risk factors with segment-specific intimal-medial thickness of the extracranial carotid artery. Stroke (1999) 1.20
Pravastatin, lipids, and major coronary events. Am J Cardiol (1994) 1.20
Regional sympathetic function in high spinal cord injury during mental stress and autonomic dysreflexia. Brain (1998) 1.19
Finger tendon disease in untreated early rheumatoid arthritis: a comparison of ultrasound and magnetic resonance imaging. Arthritis Rheum (2007) 1.19
Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke (1996) 1.19
Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism (1982) 1.19
Prevalence of migraine. J Neurol Neurosurg Psychiatry (1975) 1.18
Sympathetic muscle nerve activity, peripheral blood flows, and baroreceptor reflexes in humans during propofol anesthesia and surgery. Anesthesiology (1994) 1.17
Postmenopausal estrogen administration suppresses muscle sympathetic nerve activity. J Clin Endocrinol Metab (2001) 1.16
Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med (1987) 1.16
Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med (1985) 1.15
Loss of 7-methylguanine from rat liver DNA after methylation in vivo with methylmethanesulphonate or dimethylnitrosamine. Chem Biol Interact (1973) 1.15
Renal duplex sonography: evaluation of clinical utility. J Vasc Surg (1990) 1.14
Tubulin domains responsible for assembly of dimers and protofilaments. EMBO J (1985) 1.14
The detection of alkylation damage in the DNA of human gastrointestinal tissues. Br J Cancer (1991) 1.13
Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb (1991) 1.12
EEG theta rhythm in infants and preschool children. Clin Neurophysiol (2006) 1.12